Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

COVID-19 and the nicotinic cholinergic system

Konstantinos Farsalinos, Athina Angelopoulou, Nikos Alexandris, Konstantinos Poulas
European Respiratory Journal 2020 56: 2001589; DOI: 10.1183/13993003.01589-2020
Konstantinos Farsalinos
Laboratory of Molecular Biology and Immunology, Dept of Pharmacy, University of Patras, Patras, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Konstantinos Farsalinos
Athina Angelopoulou
Laboratory of Molecular Biology and Immunology, Dept of Pharmacy, University of Patras, Patras, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Athina Angelopoulou
Nikos Alexandris
Laboratory of Molecular Biology and Immunology, Dept of Pharmacy, University of Patras, Patras, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nikos Alexandris
Konstantinos Poulas
Laboratory of Molecular Biology and Immunology, Dept of Pharmacy, University of Patras, Patras, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The prevalence of smoking among hospitalised COVID-19 patients is low. COVID-19 manifestations could be linked to impairment of the cholinergic anti-inflammatory pathway. Nicotinic cholinergic agonists should be examined as potential therapeutic options. https://bit.ly/2zfUZ1S

To the Editor:

We have read with great interest the paper by Leung et al. [1] published in the European Respiratory Journal, the correspondence by Russo et al. [2], and also the subsequent comment by the first group [3]. Both research teams are reporting increased angiotensin-converting enzyme 2 (ACE-2) expression in airways of current smokers and those with COPD, with important implications for coronavirus disease 2019 (COVID-19) patients. Since ACE-2 has been shown to be the main receptor utilised by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter the host cells [2], the authors conclude that nicotine is a risk factor for COVID-19. Russo et al. [2] have shown that nicotine upregulates ACE-2 through α7-nAChRs which are present in neuronal and non-neuronal cells. Leung et al. [3] provided further evidence in support of this hypothesis and propose the repurposing of α7-nAChR antagonists for the pandemic (e.g. methyllycaconitine, α-conotoxin), expecting that such treatment will alter ACE-2 expression and prevent SARS-CoV-2 entry.

While this hypothesis is based on laboratory experiments, it is not supported by clinical data. Recent observations on the prevalence of smoking among hospitalised COVID-19 patients have raised some important issues. Many studies, while based on preliminary data and subject to several limitations (e.g. lack of adjustment for confounding factors, possibility for inability to report, inaccurate recording or under-reporting of the smoking status), suggest that the proportion of hospitalised COVID-19 patients who are current smokers is by far lower than expected based on population smoking rates [4, 5]. In one study, smoking was associated with lower odds of hospitalisation for COVID-19 after adjusting for covariates [6].

To further address this issue, we calculated the pooled prevalence of current smoking in 11 published case series (table 1), nine from China and two from the USA [5–15], and compared it to the expected prevalence based on gender-adjusted and gender- and age-adjusted population smoking rates in each country by estimating the prevalence odds ratio (POR) using random effects meta-analysis. Due to the lack of data on patients’ age distribution, the age-adjustment for the expected smoking prevalence was calculated by assuming that all patients were aged ≥65 years, since lower smoking prevalence is observed in the elderly compared to younger adult age groups. Population smoking prevalence information was derived from the World Health Organization 2018 Global Adult Tobacco Survey [16] for China, and from the US Centers for Disease Control and Prevention (for gender adjustment) [17] and Statista (for gender and age adjustment) [18]. The pooled prevalence of smoking was 5.3% (95% CI 3.2–8.0%), while the gender adjusted POR was 0.16 (95% CI 0.12–0.23; p<0.001) and the gender- and age-adjusted POR was 0.20 (95% CI 0.14–0.30; p<0.001). Despite the many limitations, these observations need to be taken into consideration. Recently, a hypothesis that the nicotinic cholinergic system may be involved in COVID-19 infection was presented, based on the fact that several of the symptoms and clinical signs of COVID-19, including the cytokine storm, could be explained by dysfunction of the cholinergic anti-inflammatory pathway [19]. α7-nAChRs are potentially involved in modulating pro-inflammatory cytokine secretion and suppressing the cytokine storm [20, 21]. Additional clinical manifestations of COVID-19 (such as anosmia and thromboembolic complications) can also be associated with dysfunction of the nicotinic cholinergic system [19].

View this table:
  • View inline
  • View popup
TABLE 1

Studies used to estimate the pooled prevalence and the prevalence odds ratio of current smoking among hospitalised coronavirus disease 2019 patients

In conclusion, the observations of a low smoking prevalence among hospitalised COVID-19 patients, despite the important limitations, together with the hypothetical links between dysfunction of the nicotinic cholinergic system and clinical manifestations of the disease raise some important research questions, considering that nicotine is a cholinergic agonist. The interaction between SARS-CoV-2 and the nicotinic cholinergic system should be further examined and any proposal for the repurposing of α7-nAChR antagonists should be approached with caution, since it could potentially propagate the cytokine storm and adversely affect the prognosis. Obviously, smoking cannot be considered protective for COVID-19 (or any other disease), but pharmaceutical nicotine products are widely available and their role in COVID-19 should be explored.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-01589-2020.Shareable

Footnotes

  • Conflict of interest: K. Farsalinos has nothing to disclose.

  • Conflict of interest: A. Angelopoulou has nothing to disclose.

  • Conflict of interest: N. Alexandris has nothing to disclose.

  • Conflict of interest: K. Poulas has nothing to disclose.

  • Received May 5, 2020.
  • Accepted May 10, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Leung JM,
    2. Yang CX,
    3. Tam A, et al.
    ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020; 55: 200688. doi:10.1183/13993003.00688-2020
    OpenUrl
  2. ↵
    1. Russo P,
    2. Bonassi S,
    3. Giacconi R, et al.
    COVID-19 and smoking: is nicotine the hidden link? Eur Respir J 2020; 55: 2001116. doi:10.1183/13993003.01116-2020
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Leung JM,
    2. Yang CX,
    3. Sin DD
    . COVID-19 and nicotine as a mediator of ACE-2. Eur Respir J 2020; 55: 2001261. doi:10.1183/13993003.01261-2020
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Farsalinos K,
    2. Barbouni A,
    3. Niaura R
    . Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med 2020; in press [https://doi.org/10.1007/s11739-020-02355-7]. doi:10.1007/s11739-020-02355-7
  5. ↵
    Centers for Disease Control and Prevention. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 382–386. doi:10.15585/mmwr.mm6913e2
    OpenUrlCrossRefPubMed
  6. ↵
    1. Petrilli CM,
    2. Jones SA,
    3. Yang J, et al.
    Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv 2020; preprint [https://doi.org/10.1101/2020.04.08.20057794]. doi:10.1101/2020.04.08.20057794
    1. Guan W-J,
    2. Ni Z-Y,
    3. Hu Y, et al.
    Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720. doi:10.1056/NEJMoa2002032
    OpenUrlPubMed
    1. Chen T,
    2. Wu D,
    3. Chen H, et al.
    Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1091. doi:10.1136/bmj.m1091
    OpenUrlAbstract/FREE Full Text
    1. Zhou F,
    2. Yu T,
    3. Du R, et al.
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062. doi:10.1016/S0140-6736(20)30566-3
    OpenUrlCrossRefPubMed
    1. Mo P,
    2. Xing Y,
    3. Xiao Y, et al.
    Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020; in press [https://doi.org/10.1093/cid/ciaa270]. doi:10.1093/cid/ciaa270
    1. Zhang JJ,
    2. Dong X,
    3. Cao YY, et al.
    Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; in press [https://doi.org/10.1111/all.14238]. doi:10.1111/all.14238
    1. Wan S,
    2. Xiang Y,
    3. Fang W, et al.
    Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020; 92: 797–806. doi:10.1002/jmv.25783
    OpenUrlCrossRefPubMed
    1. Liu W,
    2. Tao Z-W,
    3. Lei W, et al.
    Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020; 133: 1032–1038. doi:10.1097/CM9.0000000000000775
    OpenUrl
    1. Huang C,
    2. Wang Y,
    3. Li X, et al.
    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. doi:10.1016/S0140-6736(20)30183-5
    OpenUrlCrossRefPubMed
  7. ↵
    1. Zhang X,
    2. Cai H,
    3. Hu J, et al.
    Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis 2020; 94: 81–87. doi:10.1016/j.ijid.2020.03.040
    OpenUrlCrossRefPubMed
  8. ↵
    World Health Organization. Global Adult Tobacco Survey. Fact sheet China 2018. www.who.int/docs/default-source/wpro---documents/countries/china/2018-gats-china-factsheet-cn-en.pdf?sfvrsn=3f4e2da9_2 Date last accessed: 6 May, 2020.
  9. ↵
    1. Creamer MR,
    2. Wang TW,
    3. Babb S, et al.
    Tobacco product use and cessation indicators among adults — United States, 2018. MMWR Morb Mortal Wkly Rep 2019; 68: 1013–1019. doi:10.15585/mmwr.mm6845a2
    OpenUrlPubMed
  10. ↵
    Statista. Percentage of adults in the US who were current cigarette smokers as of 2016, by age and gender. www.statista.com/statistics/673619/smoking-prevalence-among-men-us-by-age/ Date last accessed: 6 May, 2020.
  11. ↵
    1. Farsalinos K,
    2. Niaura R,
    3. Le Houezec J, et al.
    Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep 2020; 30: 658–663. doi:10.1016/j.toxrep.2020.04.012
    OpenUrl
  12. ↵
    1. Tracey KJ
    . The inflammatory reflex. Nature 2002; 420: 853–859. doi:10.1038/nature01321
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Kalamida D,
    2. Poulas K,
    3. Avramopoulou V, et al.
    Muscle and neuronal nicotinic acetylcholine receptors: structure, function and pathogenicity. FEBS J 2007; 274: 3799–3845. doi:10.1111/j.1742-4658.2007.05935.x
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 1 Table of Contents
European Respiratory Journal: 56 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 and the nicotinic cholinergic system
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
COVID-19 and the nicotinic cholinergic system
Konstantinos Farsalinos, Athina Angelopoulou, Nikos Alexandris, Konstantinos Poulas
European Respiratory Journal Jul 2020, 56 (1) 2001589; DOI: 10.1183/13993003.01589-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
COVID-19 and the nicotinic cholinergic system
Konstantinos Farsalinos, Athina Angelopoulou, Nikos Alexandris, Konstantinos Poulas
European Respiratory Journal Jul 2020, 56 (1) 2001589; DOI: 10.1183/13993003.01589-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society